Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyQuantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistancePractical management of patients with myelofibrosis receiving ruxolitinib.Safety evaluation of ruxolitinib for treating myelofibrosis.Practical management of myelofibrosis with ruxolitinib.Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.Molecular therapy for acute myeloid leukaemia.Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicEmerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesA phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemiaCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Interleukin-6--a key regulator of colorectal cancer development.Head and neck cancer: from anatomy to biology.Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.STAT3 inhibitors: finding a home in lymphoma and leukemia.STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Definition and management of ruxolitinib treatment failure in myelofibrosis.Targeting novel signaling pathways for resistant acute myeloid leukemia.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Immunological Consequences of JAK Inhibition: Friend or Foe?Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.
P2860
Q26749870-8F715237-087D-4108-9832-783569E38D2EQ30436867-1431C02D-605B-4871-965A-5F8CE3FE7083Q30666276-B5E9B841-B870-439C-B387-82819114227AQ33410649-E495DAA8-B690-488B-AA20-AE5AF0415082Q33415731-AAABAD6C-B33B-461B-92E5-83B1F4B8EDC5Q33428259-4E63F93D-93C7-43E1-8BC4-DAC7726E13C2Q33556931-026738F8-09B4-45B4-BA39-027327A4EC81Q33798544-A32BB336-AC9B-4599-81DB-F39A35D65167Q33917530-896FE6E1-27A1-4F2D-AFD6-6271BAE99584Q33925672-80B49832-32E3-47B7-9E22-D8DB30FFEC79Q34642403-DC8BB762-AEC6-4CB1-BB73-1D9AE37B4F90Q34752547-A0F08612-D783-4FE9-9674-ECDCD9A872A4Q34817365-09A841C1-E2C5-4D5F-A408-1CF9EB44839DQ35132241-5F240D2C-A66D-4CB2-9070-FBD80CEFBE6FQ35132525-F9F6561F-D701-4273-8572-072413A3770DQ35546759-D2BFB673-58F1-4D07-9387-86CC0B69C949Q35988523-E80F52A9-2D66-4224-8CA4-FCACEB20A587Q36708989-6729E9AE-F0C6-4D9D-A1DE-1A3804EF765CQ37349392-8B6253C9-A4C7-4A81-8D2F-28952AEBA79AQ37555790-0AE89197-9328-4022-A9E1-2660AFDBBABEQ37676277-C8671A50-9D05-459A-83D7-01B38EFB53F0Q37693266-8DFFD1CA-B260-44EA-B89B-B5CACAB92C62Q37704373-C25AACA6-0E0B-4C31-A143-B5BC1D82AB68Q38044736-6EC2EC95-BBD0-45D1-84BC-20F4003DAD21Q38058510-8C293C3C-5834-4546-9110-A59C8E47CB2DQ38082457-88FD6FA1-BFC5-4DC5-B5D0-4CF12B542D35Q38097735-F1E65845-1058-43AB-8635-6711D6DD1657Q38100790-5C97830E-38F8-4FBB-8960-57C2764BF913Q38116768-11D6C3B7-C4E1-41E9-8C64-CB4A49F85C22Q38164139-2350F9B6-0CAA-4602-8604-AB8459064DE5Q38202556-5ECEE39B-6FCE-4EEA-8FC2-476C485071F0Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1Q38267888-2BB961E6-345D-49B3-B6AA-CDDE2A782367Q38287012-1827D2AF-640B-4B8F-BA88-8EAE1BF43547Q38297507-B4E28AF2-71DB-419D-A252-7D6400C64356Q38349213-31ECDE34-134B-4C1D-B0E0-B186619F0400Q38401664-018A0EE2-1BC7-4D0B-BF50-9136D39E4CBAQ38429716-0AA46D32-F9F9-4C06-8266-989011A4E223Q38570383-8ABA7A75-BE83-4337-8F0E-3A04AA24D201Q38844669-8C8A2ADA-D3CA-4A03-A05F-68D98D5F751A
P2860
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@en
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@nl
type
label
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@en
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@nl
prefLabel
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@en
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@nl
P2093
P2860
P50
P921
P1433
P1476
Phase 2 study of the JAK kinas ...... oplasm acute myeloid leukemia.
@en
P2093
Alireza Eghtedar
Carol Bivins
Jan Burger
Peggy A Scherle
Robert C Newton
Solly George
P2860
P304
P356
10.1182/BLOOD-2011-12-400051
P407
P50
P577
2012-03-15T00:00:00Z